We remain bullish on SUN’s Healthcare sector, which will receive a boost with the IFC investment of LKR 3.3bn. Expansions in pharma manufacturing in particular are expected to elevate the long term group value. We believe the contribution from Tea exports will grow steadily with improved volumes and demand recovery, despite short term setback from LKR appreciation. We reiterate BUY with a TP of LKR 86.00 on SOTP valuation.